Kornimate/medical-research-clean huggingface dataset:
examining parkinson's disease-related retirement: results of turkey

Conditions: Parkinson Disease

Summary: although parkinson disease's (pd) is usually associated with an older patient population, 5% of patients are diagnosed at age 50 and 30% before 65 years of age. this shows that many patients with pd have diagnosed during the active study and have long periods of normal retirement. after the diagnosis of parkinson's patients, the duration of leaving of employment vary between 0 and 25 years. it was found that patients' full-time working capacity decreased by up to 80% and they quitted earlier than the general population. the disability associated with pd is thought to be a factor in this situation. nevertheless, the reasons for early retirement are not fully known and more information is needed on the specific problems of pd in order for patients to continue their career. the aim of our study is to examine the impact of parkinson's disease on retirement and to contribute to turkey's data. patients with pd admitted to the parkinson's disease outpatient clinic, which is the biggest clinic of turkey about neurology, are included in the study. it is planned to meet with 75 patients on 31/12/2018 and to reach the end of the data collection phase.


Eligibility criteria:
inclusion criteria: * to be between 30-85 aged * parkinson disease diagnosis according to the united kingdom brain bank criteria * to be treated with antiparkinson exclusion criteria: * dementia * severe cognitive impairment * not willing to participate in the study

Keywords: parkinson disease, early retirement,
auscultation and pulse oximetry combined screening of neonatal congenital heart disease

Conditions: Congenital Heart Disease

Summary: the investigators conducted this retrospective study in a large single center with an annual birth of more than 20,000 newborns, from january 1, 2018 to december 31, 2019, to confirm the applicability and accuracy of pulse oximetry (pox) combined cardio-auscultation to screen congenital heart disease for neonates.

all consecutive newborn babies were eligible, irrespective of gestational age, nicu admission, symptom presence or prenatal diagnosis. this study was approved by institutional ethical review board of linyi maternal and child healthcare hospital. spoken informed consent was obtained from the participating babies' parents. physicians from departments of neonatal medicine and developmental medicine undertake auscultation screening. when abnormal murmur occurred, an echocardiography would be requested to confirm if the newborn has chd or not. physicians from obstetrics department and nursing staff from neonatal department undertake pox measurement. if a positive pox occurred, an echocardiography would be requested to confirm if the newborn has chd or not. physicians from department of ultrasonography undertake echocardiography confirmation for newborns deemed positive by auscultation or pox.

Eligibility criteria:
inclusion criteria: * all consecutive newborn babies delivered in the study center were eligible, irrespective of gestational age, nicu admission, symptom presence or prenatal diagnosis. exclusion criteria: * none.

Keywords: pulse oximetry auscultation congenital heart disease screening
observational study to evaluate the effectiveness and safety of levemir®, novomix® 30 and novorapid® in insulin naïve subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe and asia. the aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using levemir®, novomix® and/or novorapid® in subjects with type 2 diabetes that have not used insulin previously under normal clinical practice conditions.


Eligibility criteria:
inclusion criteria: * any insulin näive type 2 diabetic patient that able to use the drug as judged by the investigator exclusion criteria: * in accordance with approved label
the effect of pert on patients undergoing pancreaticoduodenectomy

Conditions: Pancreatic Exocrine Insufficiency; Pancreatic Enzyme Replacement Therapy; Pancreaticoduodenectomy

Summary: a comprehensive perioperative nutrition management plan for pancreaticoduodenectomy, primarily based on pancreatic enzyme replacement therapy (pert). a prospective randomized controlled study was conducted to comprehensively analyze the perioperative nutritional status of patients undergoing pancreaticoduodenectomy, with the aim of exploring: 1. the effect of pert on postoperative complications and physiological status after pancreaticoduodenectomy; 2. the efficacy of pert treatment on clinical symptoms, nutritional indicators, and quality of life (qol) related to pancreatic exocrine dysfunction (pei) after pancreaticoduodenectomy; 3. the personalized full process nutrition management strategies based on risk factor stratification.


Eligibility criteria:
inclusion criteria: * gender unlimited, 18-80 years old; * patients undergoing pancreaticoduodenectomy due to various benign or malignant diseases; * voluntary testing with informed consent. exclusion criteria: * pregnant women and lactating women * patients with distant metastasis based on tumor staging before surgery; * tumor recurrence; * refuse to sign the consent form.
treatment with sitagliptin for reactive hypoglycemia secondary to dysinsulinism

Conditions: Reactive Hypoglycemia

Summary: the purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.

symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion. patients with this abnormality as an early manifestation of glucose intolerance are at higher risk of type 2 diabetes. the pathophysiology of this abnormality appears to be related with delayed first phase insulin release. improvement of first phase insulin secretion and delay in gastric emptying induced by sitagliptin phosphate could have favorable effects in patients in whom delayed insulin secretion is associated with reactive hypoglycemia.

Eligibility criteria:
inclusion criteria: * clinical and biochemical diagnosis of prediabetic reactive hypoglycemia * must be able to swallow tablet * negative pregnancy test (when appropriate) exclusion criteria: * renal insufficiency * hepatic insufficiency * diabetes (any type)

Keywords: reactive hypoglycemia sitagliptin glucagon-like peptide 1 incretins prediabetes
long-term follow-up nirs-ivus imaging of pre-existing carotid stents

Conditions: Carotid Atherosclerosis; Carotid Artery Stenting; Atherosclerotic Plaque; Near Infrared Spectroscopy; Restenosis

Summary: the 'long-term follow-up near-infrared spectroscopy and intravascular ultrasound imaging of internal carotid artery stenosis treated with stenting' trial is an academic research project. it follows already published results of a research on carotid plaque composition in patients undergoing carotid stenting. patients who were treated with carotid stenting will be invited to participate on the trial. the written informed consent will be needed. the participants will undergo carotid angiography, intravascular near-infrared spectroscopy and intravascular ultrasound of the extracranial portion of the internal and common carotid artery with implanted stent. the aim of the trial is to describe long-term change of the luminal and stent dimensions, vessel wall remodeling and plaque composition after carotid stenting. the findings will help to understand the long-term effect of carotid stenting on the carotid stenosis and mechanisms of plaque stabilization - sealing with stent.


Eligibility criteria:
inclusion criteria: * previous carotid stenting * data from periprocedural nirs-ivus available * written informed consent exclusion criteria: * occlusion of the carotid artery on the side of the implanted stent * indication for carotid intervention on the side of the implanted stent * high procedural risk (difficult anatomy, risk of puncture site bleeding)
compare efficacy and safety of telmisartan/hydrochlorothiazide with telmisartan/hydrochlorothiazide plus amlodipine

Conditions: Hypertension

Summary: this is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (fdc) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg (t80/a5/h12.5 mg) to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg (t80/h12.5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg. patients are assigned to one of the two groups after a 6-week open-label run-in period taking t80/h12.5 mg. in addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide 12.5 mg will be evaluated in a 52-week extension period. in the 52-week open label extension period patients who are assigned to the t80/a5/h12.5 mg group continue the t80/a5/h12.5 mg therapy, and patients who are assigned to the t80/ /h12.5 mg group change to the t80/a5/h12.5 mg therapy.


Eligibility criteria:
inclusion criteria: 1. essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (dbp) must be \>=90 and \<=114 mmhg and mean seated systolic blood pressure (sbp) must be =\<200 mmhg 2. able to stop all current antihypertensive drugs (other than study medication) from visit 1b through the end of the trial without risk to the patient based on the investigator's opinion 3. age 20 years or older exclusion criteria: 1. patients with known or suspected secondary hypertension 2. patients with clinically relevant cardiac arrhythmia 3. congestive heart failure with new york heart association (nyha) functional class iii-iv 4. patients with recent cardiovascular events 5. patients with recent stroke events 6. patients with a history of sudden deterioration of renal function with angiotensin ii receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy 7. patients with hepatic and/or renal dysfunction 8. pre-menopausal women who are nursing or pregnant
bortezomib to treat significant complication of hsct

Conditions: Allogeneic Stem Cell Transplantation; Refractory Autoimmune Cytopenia(s)

Summary: the purpose of this trial is to study the safety and effectiveness of a drug called bortezomib for the treatment of low blood cell counts after bone marrow transplant.

the purpose of this research study is to study the safety and effectiveness of a drug called bortezomib for the treatment of autoimmune cytopenia(s) (low blood cell counts) after bone marrow transplant that are not responding to standard treatments. autoimmune cytopenias are low blood counts due to antibodies or proteins produced against an individual's own blood cells. having a low red blood cell count (anemia) can make a person feel tired and require blood transfusions frequently. a low platelet count (blood cells that help blood to clot) can make a person bleed or bruise easily. a low neutrophil (white blood cell) count can make a person have infections. all of these things can be a serious complication after bone marrow transplant and can cause prolonged hospital stay. bortezomib is being used in children with certain types of blood cancer, however, bortezomib has not been used in children with autoimmune cytopenia(s) and its use in this study is investigational.

Eligibility criteria:
inclusion criteria: * all patients, having undergone allogeneic stem cell transplantation at our center. * should have failed at least 2 standard treatments for autoimmune cytopenias. standard treatments include corticosteroids, rituximab, ivig, plasmapheresis, withdrawal of cyclosporine, cyclophosphamide and mmf. definition of "failed" treatment will be no response of cytopenia after 2 weeks of continued treatment or requirement of daily gcsf at 10 mcgs/kg/day for autoimmune neutropenia despite 2 weeks of treatment, transfusions of packed red blood cells or platelets 3 times weekly for 2weeks despite continued treatment or 5days/week plasmapheresis for 2 weeks and inability to wean the duration. * definition of autoimmune hemolytic anemia- development of anemia, where there is a hemoglobin drop of \>2 g/dl/48 hours or an absolute value of hemoglobin \< 8 g/dl, and evidence of hemolysis by positive direct coombs test with compatible peripheral blood cell morphology, reticulocyte count and bilirubin level. * definition of autoimmune neutropenia - absolute neutrophil counts \< 500 for 2 weeks and presence of anti-neutrophil antibodies. * definition of autoimmune thrombocytopenia- platelet counts \< 20,000 cells/ul for 2 weeks and presence of anti-platelet antibodies. exclusion criteria: * ongoing life threatening infections * documented anaphylaxis to bortezomib * failed engraftment * relapse of primary malignancy * ≥6/8 matched or haploidentical transplants

Keywords: hsct cytopenia immune suppression proteasome inhibitor
use ear acupuncture as treatment for low back pain during pregnancy

Conditions: Pregnancy Related Low Back Pain

Summary: ear acupuncture can be used as a treatment for pregnancy induced low back pain.

ear acupuncture has been used as treatment for various pain symptoms. pregnancy related low back pain can be debilitating for pregnant women but there is lack of effective treatment. owing to the unique circulation system between mother and fetus, prenatal care providers and gravidae are reluctant to prescribe or accept the pharmacological intervention. thus the goal of this clinical investigation is to determine whether ear acupuncture can be used as treatment for this special clinical entity. the participants are randomized into one of the three interventions based on a computer generated randomization table. these three interventions groups are: (1) true acupuncture (2) sham acupuncture and (3) no acupuncture. all participants are allowed to use standard of care (soc) as a rescue treatment and the soc consists of acetaminophen 650 mg every 6 hours no more than 4 times per day, frequent rest and topical warm/cold compress. the participants in group 1 \& 2 received a total of three continuous retained ear acupuncture needles at three sites ipsilateral to the dominant hand in preselected ear acupuncture points for one week then after day 7. all participants are followed/observed for a total 2 weeks after the initiation of the study.

Eligibility criteria:
inclusion criteria: * english speaking, healthy pregnant women in at least 25 weeks of gestational age who suffered from low back pain related to pregnancy. * no obstetric complications during pregnancy or neurological complications that require immediate medical/surgical intervention. exclusion criteria: * non-english speaking * mentally challenged * state of pregnancy less than 25 weeks but suffer from pregnancy related low back pain * pregnant women without low back pain * the pregnancy is complicated by obstetrical problems, or low back pain requiring immediate surgical/medical intervention.

Keywords: auricular acupuncture pregnancy related low back pain acupuncture
the effect and safety of low-level laser therapy in acute decompensated heart failure patients.

Conditions: Heart Failure; Acupuncture

Summary: the advantages of laser acupuncture are a non-invasive, painless, low risk of infection and high safety. laser acupuncture as a treatment tool has the following advantages1.painless, 2. non-invasive treatment, the subject is highly accepted, the risk of infection and needle stick is low, 3. very few side effects such as fainting, bleeding, 4. the therapeutic dose is easy to operate, and the instrument output frequency, power and time can be controlled. through the clinical physiological function test plus the verification and analysis of the quantitative test values, it will be more able to define the new role of laser acupuncture treatment in patients with heart failure from the perspective of chinese medicine.

from the perspective of ancient books, the discussion of heart failure in the etiology and pathogenesis of traditional chinese medicine was first seen in the "shu wen". it is clearly pointed out that "heart qi" is the basic pathogenesis of heart failure. the "qi" and "blood" of chinese medicine are closely related. the blood line is driven by the gas, the blood is bloody, and the qi deficiency is unable to push the blood to blood. if the qi deficiency, it would lead to blood stasis; there were studies have indicated that traditional acupuncture treatment can increase exercise tolerance and adjust autonomic nerve activity in patients with chronic heart failure, and can reduce their readmission rate and mortality rate in patients with acute heart failure. studies using laser acupuncture to treat patients with heart failure have also found that they can increase the subject's six-minute walking distance.

Eligibility criteria:
inclusion criteria: * age over 20 years of age, with written informed consent. * nyha:stage ii-iii. * all patients had lvef \<40% caused by dilated or ischemic cardiomyopathy. * acute hf patient presenting with dyspnea related to cardiogenic pulmonary edema. * all patients had sinus rhythm, were stable and compensated with individually optimized standard heart failure medication as well as oral anticoagulants for at least 3 months before (including prophylactic defibrillator placement). * systolic blood pressure \> 95 mmhg at admission. * b-type natriuretic peptide (bnp) \> 150 pg/ml or nt-pro bnp \> 600 pg/ml. exclusion criteria: * age under 20. * major cardiovascular events and treatments occurred four weeks before hospitalization. * major cardiovascular surgery or treatment will be performed in the next 6 months. * pregnant or expected to pregnancy within a year. * require a heart transplant in 6 months. * uncontrolled atrial or ventricular dysrhythmias. * uncompensated congestive heart failure. * heart failure due to congenital heart disease or obstructive myocardial disease

Keywords: low-level laser acupuncture therapy heart failure
coflex ps3 actual conditions for use study

Conditions: Spinal Stenosis Lumbar

Summary: a 2 and 5 year evaluation of clinical outcomes in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with additional stabilization using the coflex® interlaminar technology for fda actual conditions of use study.

a prospective, multi center, concurrently enrolled, propensity score controlled through month 60. the purpose is to fully characterize safety and efficacy then the coflex device is used in the intended subject population under actual conditions of use.

Eligibility criteria:
inclusion criteria: 1. radiographic confirmation of at least moderate lumbar stenosis at one or two contiguous levels from l1-l5 that require surgical decompression. 2. visual analog scale back pain score of at least 50 mm on a 100 mm scale. 3. neurogenic claudication as defined by leg/buttocks or groin pain that can be relieved by flexion such as sitting in a chair. 4. subject has undergone at least one lumbar injection at any prior time point, and/or at least 6 months of prior conservative care without adequate and sustained symptom relief. 5. skeletally mature 6. oswestry low back pain disability questionnaire score of at least 20/50 (40%). 7. psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures. 8. personally signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the trial. exclusion criteria: 1. prior fusion or decompressive laminectomy at index lumbar level. 2. radiographically compromised vertebral bodies at any lumbar level(s) caused by current or past trauma or tumor (e.g., compression fracture). 3. severe facet hypertrophy that requires extensive bone removal which would cause instability. 4. isthmic spondylolisthesis or spondylolysis (pars fracture). 5. degenerative lumbar scoliosis (cobb angle of greater than 25°). 6. osteoporsis or is at increased risk of osteoporosis. 7. back or leg pain of unknown etiology. 8. axial back pain only, with no leg, buttock, or groin pain. 9. morbid obesity defined as a body mass index \> 40. 10. known allergy to titanium, titanium alloys, or mr contrast agents. 11. active or chronic infection - systemic or local. 12. cauda equina syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction.

Keywords: moderate lumbar stenosis neurogenic claudication spinal stenosis low back pain decompression
examining cortisol and alpha amylase in a healthy sample of youth and adults

Conditions: Anxiety

Summary: the purpose of this study is to investigate how healthy youth and adults' cortisol levels and other hormone levels relate to anxiety levels while they participate in a behavioral task called the trier social stress task. data from these healthy participants will also be compared to those of anxious youth and adults collected as part of the in the principal investigator's ongoing study titled, "child/adolescent anxiety multimodal extended long-term study (na00035687)."

the aim of this study is to investigate the independent and interactive associations linking salivary cortisol (a marker of hypothalamic-pituitary-adrenal activity or hpa activity) and alpha amylase (a marker of autonomic nervous system activity or ans activity) in a sample of healthy controls. data from these healthy controls will be compared in the future to clinically anxious youth. in this study, participants are asked to complete a one-time assessment consisting of interviews, questionnaires, and a behavioral task (called the trier social stress task) involving a short public speaking task and an arithmetic task in front of study staff. throughout the behavioral task, study staff will collect four, small saliva samples using a straw-like tube from each participant. the assessment will take approximately 3 hours. participants will be fully debriefed regarding the purposes of the stress procedure and assessed for any signs of residual distress. since there is no treatment or randomization, blinding of study staff is not applicable. participation in this study will not affect any current or future medical or psychiatric treatment. aims: to examine whether a) salivary cortisol and alpha amylase response and recovery to the trier social stress task is associated with anxiety in non-psychiatrically ill participants.

Eligibility criteria:
inclusion criteria: * participant has no current psychiatric disorder * participant has no past psychiatric disorder * participant has no major medical disorder * participant is not currently receiving psychological or psychopharmacological treatment (medication) for any psychological disorder * participant is between the ages 11 and 34 exclusion criteria: * participant has or has had psychiatric disorder or medical condition contraindicating study participation * participant is pregnant * participant is not an english speaker * participant has a visual, motor, or hearing problem that would affect participation
the effect of icon treatment on wpl with patients after fixed orthodontic appliances

Conditions: White Spot Lesion

Summary: the aim of this study is to determine the effect of icon on white spot lesions compared to cpp-acpf plus.

the participants were categorized to either group (group1) receiving icon treatment method (icon, dmg, germany), or (group 2) who shall be receiving cpp-acpf treatment method (tooth mousse plus).

Eligibility criteria:
inclusion criteria: * permanent dentition, in good general health and without systemic diseases, who had received fixed orthodontic treatment. exclusion criteria: * patients with primary dentition, enamel hypoplasia, dental fluorosis or tetracycline pigmentation and carious cavity were excluded.